GU Cancers 2024 | Management of immunotherapy-related adverse events in RCC

Viktor Grünwald, MD, University Hospital Essen, Essen, Germany, comments on adverse reactions to immunotherapy in renal cell carcinoma (RCC). Whilst combination immunotherapy and tyrosine kinase inhibitors (TKIs) are effective in treating RCC, combining these agents may increase the severity of associated adverse events such as diarrhea. Monitoring patients is essential to manage these toxicities. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.